{
  "nctId": "NCT03055767",
  "briefTitle": "Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population",
  "officialTitle": "Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Randomized Double Blinded Placebo Cross-over Study in the Pediatric Pain Population",
  "protocolDocument": {
    "nctId": "NCT03055767",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-01-20",
    "uploadDate": "2023-05-31T16:09",
    "size": 2535190,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03055767/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 17,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-03-01",
    "completionDate": "2020-04-20",
    "primaryCompletionDate": "2018-11-30",
    "firstSubmitDate": "2017-02-08",
    "firstPostDate": "2017-02-16"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Children aged 8 - 17 years of age with a history of migraine meeting the criteria established in ICHD-II (2004), Section 1. Patients will provide at least 28-day baseline data in the form in the daily diary and must have at least 15 days of reported headache during this period, with at least 4 distinct episodes lasting at least 4 hours each.\n\nExclusion Criteria:\n\n* Previous use of botulinum toxin of any serotype for any reason\n* Pregnancy.\n* Diagnosis of Myasthenia gravis, Eaton Lambert Syndrome, Amyotrophic Lateral Sclerosis\n* Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week of screening visit",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "8 Years",
    "maximumAge": "17 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Frequency of Migraines",
        "description": "The frequency of migraines in days.",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Intensity of Migraines",
        "description": "Median intensity of migraines based on 0-10 Pain Numeric Rating Score (NRS). The higher the score, the more intense the pain.",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Migraine Duration, in Hours",
        "description": "Duration of migraines in hours.",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Pediatric Migraine Disability Score (PedMIDAS)",
        "description": "Pediatric Migraine Disability Score consists of 6 questions: 3 addressing school attendance and functioning, and 3 evaluating participation in events outside of school. The questionnaire is based on the patient's recall of the previous 3 months.\n\nThe questionnaire produces a raw score (0-10, 11-30, 31-50, \\>50) corresponding to a disability grade with increasing severity (little to non, mild, moderate, and severe) which was coded (1, 2, 3, and 4).",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      }
    ],
    "secondary": [
      {
        "measure": "Functionality Improvement",
        "description": "Improvement of functionality as determined by their Pediatric Migraine Disability Score (PedMIDAS). The PedMIDAS consists of 6 questions: 3 addressing school attendance and functioning, and 3 evaluating participation in events outside of school. The questionnaire is based on the patient's recall of the previous 3 months.\n\nThe questionnaire produces a raw score (0-10, 11-30, 31-50, \\>50) corresponding to a disability grade with increasing severity (little to non, mild, moderate, and severe) which was coded (1, 2, 3, and 4).",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Difficulty Sleeping",
        "description": "Subject reported having difficulty sleeping",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Hospital Admissions",
        "description": "Admission to hospital",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Emergency Department (ED) Visits",
        "description": "Subject visited an Emergency Department",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Home School",
        "description": "Subject is home schooled full-time.",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post, respective intervention"
      },
      {
        "measure": "School Plan Enrollment",
        "description": "Subject is enrolled in a school plan such as IEP, 504 plan, or similar modified school schedule.",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Duration of Benefit",
        "description": "The duration of benefit in weeks",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      },
      {
        "measure": "Concomitant Headache Medications",
        "description": "Number of concomitant headache medications taken",
        "timeFrame": "Baseline (4 weeks) and 12 weeks post each, respective intervention"
      }
    ],
    "other": [
      {
        "measure": "Frequency of Migraines | Open-label Period",
        "description": "The frequency of migraines during the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.",
        "timeFrame": "24-48 weeks post-baseline period"
      },
      {
        "measure": "Intensity of Migraines | Open-Label Period",
        "description": "Intensity of migraines during the the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.\n\nIntensity based on 0-10 Pain Numeric Rating Score (NRS). The higher the score, the more intense the pain.",
        "timeFrame": "24-48 weeks post-baseline period"
      },
      {
        "measure": "Pediatric Migraine Disability Score (PedMIDAS) | Open-Label Period",
        "description": "The PedMIDAS the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.\n\nThe PedMIDAS consists of 6 questions: 3 addressing school attendance and functioning, and 3 evaluating participation in events outside of school. The questionnaire is based on the patient's recall of the previous 3 months.\n\nThe questionnaire produces a raw score (0-10, 11-30, 31-50, \\>50) corresponding to a disability grade with increasing severity (little to non, mild, moderate, and severe) which was coded (1, 2, 3, and 4).",
        "timeFrame": "24-48 weeks post-baseline period"
      },
      {
        "measure": "Duration of Migraine | Open-Label Period",
        "description": "Duration of migraine in hours during the open-label period (2 additional rounds of onabotulinumtoxinA) as compared to the cross-over period.",
        "timeFrame": "24-48 weeks post-baseline period"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 4,
      "secondaryCount": 8,
      "otherCount": 4,
      "totalCount": 16
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:51.865Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}